STAT+: Legend Biotech emerged as a rare market winner
Summary
Legend Biotech jumped sharply after it reported early in vivo CAR-T data that looked promising in non-Hodgkin’s lymphoma. The move stood out against a broader biotech selloff and made the company one of the day’s rare market winners. The article places this development alongside broader biotech market and licensing activity. The key takeaway is that clinical progress can quickly change investor sentiment for biotech companies.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected